Movatterモバイル変換

[0]ホーム
URL:

WO2001055326A3 - Nucleic acids, proteins, and antibodies - Google Patents

Nucleic acids, proteins, and antibodiesDownload PDF

Info

Publication number
WO2001055326A3
WO2001055326A3PCT/US2001/001347US0101347WWO0155326A3WO 2001055326 A3WO2001055326 A3WO 2001055326A3US 0101347 WUS0101347 WUS 0101347WWO 0155326 A3WO0155326 A3WO 0155326A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
antibodies
further relates
present
novel
Prior art date
Application number
PCT/US2001/001347
Other languages
French (fr)
Other versions
WO2001055326A2 (en
WO2001055326A8 (en
Inventor
Craig A Rosen
Steven C Barash
Steven M Ruben
Original Assignee
Human Genome Sciences Inc
Craig A Rosen
Steven C Barash
Steven M Ruben
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Craig A Rosen, Steven C Barash, Steven M RubenfiledCriticalHuman Genome Sciences Inc
Priority to AU2001241414ApriorityCriticalpatent/AU2001241414A8/en
Priority to US09/908,711prioritypatent/US20020045230A1/en
Publication of WO2001055326A2publicationCriticalpatent/WO2001055326A2/en
Publication of WO2001055326A3publicationCriticalpatent/WO2001055326A3/en
Publication of WO2001055326A8publicationCriticalpatent/WO2001055326A8/en

Links

Classifications

Landscapes

Abstract

The present invention relates to novel proteins. More specifically, isolated nucleic acid molecules are provided encoding novel polypeptides. Novel polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human polynucleotides and/or polypeptides, and antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to these novel polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
PCT/US2001/0013472000-01-312001-01-17Nucleic acids, proteins, and antibodiesWO2001055326A2 (en)

Priority Applications (2)

Application NumberPriority DateFiling DateTitle
AU2001241414AAU2001241414A8 (en)2000-01-312001-01-17Nucleic acids, proteins, and antibodies
US09/908,711US20020045230A1 (en)2000-08-142001-07-20Nucleic acids, proteins, and antibodies

Applications Claiming Priority (237)

Application NumberPriority DateFiling DateTitle
US17906500P2000-01-312000-01-31
US60/179,0652000-01-31
US18062800P2000-02-042000-02-04
US60/180,6282000-02-04
US18466400P2000-02-242000-02-24
US60/184,6642000-02-24
US18635000P2000-03-022000-03-02
US60/186,3502000-03-02
US18987400P2000-03-162000-03-16
US60/189,8742000-03-16
US19007600P2000-03-172000-03-17
US60/190,0762000-03-17
US19812300P2000-04-182000-04-18
US60/198,1232000-04-18
US20551500P2000-05-192000-05-19
US60/205,5152000-05-19
US20946700P2000-06-072000-06-07
US60/209,4672000-06-07
US21488600P2000-06-282000-06-28
US60/214,8862000-06-28
US21513500P2000-06-302000-06-30
US60/215,1352000-06-30
US21688000P2000-07-072000-07-07
US21664700P2000-07-072000-07-07
US60/216,8802000-07-07
US60/216,6472000-07-07
US21749600P2000-07-112000-07-11
US21748700P2000-07-112000-07-11
US60/217,4962000-07-11
US60/217,4872000-07-11
US21829000P2000-07-142000-07-14
US60/218,2902000-07-14
US22096400P2000-07-262000-07-26
US22096300P2000-07-262000-07-26
US60/220,9642000-07-26
US60/220,9632000-07-26
US22527000P2000-08-142000-08-14
US22575700P2000-08-142000-08-14
US22575900P2000-08-142000-08-14
US22521400P2000-08-142000-08-14
US22575800P2000-08-142000-08-14
US22526700P2000-08-142000-08-14
US22526800P2000-08-142000-08-14
US22451900P2000-08-142000-08-14
US22451800P2000-08-142000-08-14
US22526600P2000-08-142000-08-14
US22544700P2000-08-142000-08-14
US22521300P2000-08-142000-08-14
US60/225,2132000-08-14
US60/225,2672000-08-14
US60/224,5182000-08-14
US60/225,2662000-08-14
US60/224,5192000-08-14
US60/225,7572000-08-14
US60/225,7582000-08-14
US60/225,7592000-08-14
US60/225,2702000-08-14
US60/225,4472000-08-14
US60/225,2682000-08-14
US60/225,2142000-08-14
US22627900P2000-08-182000-08-18
US60/226,2792000-08-18
US22668100P2000-08-222000-08-22
US22718200P2000-08-222000-08-22
US22686800P2000-08-222000-08-22
US60/226,6812000-08-22
US60/227,1822000-08-22
US60/226,8682000-08-22
US22700900P2000-08-232000-08-23
US60/227,0092000-08-23
US22892400P2000-08-302000-08-30
US60/228,9242000-08-30
US22934300P2000-09-012000-09-01
US22928700P2000-09-012000-09-01
US22934400P2000-09-012000-09-01
US22934500P2000-09-012000-09-01
US60/229,3452000-09-01
US60/229,3442000-09-01
US60/229,3432000-09-01
US60/229,2872000-09-01
US22950900P2000-09-052000-09-05
US22951300P2000-09-052000-09-05
US60/229,5092000-09-05
US60/229,5132000-09-05
US23043700P2000-09-062000-09-06
US23043800P2000-09-062000-09-06
US60/230,4382000-09-06
US60/230,4372000-09-06
US23124400P2000-09-082000-09-08
US23124300P2000-09-082000-09-08
US23208100P2000-09-082000-09-08
US23124200P2000-09-082000-09-08
US23141300P2000-09-082000-09-08
US23208000P2000-09-082000-09-08
US23141400P2000-09-082000-09-08
US60/231,2422000-09-08
US60/231,4142000-09-08
US60/232,0812000-09-08
US60/231,4132000-09-08
US60/231,2442000-09-08
US60/232,0802000-09-08
US60/231,2432000-09-08
US23196800P2000-09-122000-09-12
US60/231,9682000-09-12
US23306500P2000-09-142000-09-14
US23306300P2000-09-142000-09-14
US23239700P2000-09-142000-09-14
US23240100P2000-09-142000-09-14
US23240000P2000-09-142000-09-14
US23306400P2000-09-142000-09-14
US23239900P2000-09-142000-09-14
US23239800P2000-09-142000-09-14
US60/232,3982000-09-14
US60/232,4012000-09-14
US60/233,0632000-09-14
US60/232,3992000-09-14
US60/232,3972000-09-14
US60/232,4002000-09-14
US60/233,0642000-09-14
US60/233,0652000-09-14
US23422300P2000-09-212000-09-21
US23427400P2000-09-212000-09-21
US60/234,2742000-09-21
US60/234,2232000-09-21
US23499800P2000-09-252000-09-25
US23499700P2000-09-252000-09-25
US60/234,9982000-09-25
US60/234,9972000-09-25
US23548400P2000-09-262000-09-26
US60/235,4842000-09-26
US23583400P2000-09-272000-09-27
US23583600P2000-09-272000-09-27
US60/235,8362000-09-27
US60/235,8342000-09-27
US23636700P2000-09-292000-09-29
US23632700P2000-09-292000-09-29
US23636800P2000-09-292000-09-29
US23636900P2000-09-292000-09-29
US23637000P2000-09-292000-09-29
US60/236,3672000-09-29
US60/236,3692000-09-29
US60/236,3272000-09-29
US60/236,3702000-09-29
US60/236,3682000-09-29
US23703700P2000-10-022000-10-02
US23703900P2000-10-022000-10-02
US23704000P2000-10-022000-10-02
US23703800P2000-10-022000-10-02
US23680200P2000-10-022000-10-02
US60/236,8022000-10-02
US60/237,0392000-10-02
US60/237,0372000-10-02
US60/237,0402000-10-02
US60/237,0382000-10-02
US23993700P2000-10-132000-10-13
US23993500P2000-10-132000-10-13
US60/239,9352000-10-13
US60/239,9372000-10-13
US24178600P2000-10-202000-10-20
US24180900P2000-10-202000-10-20
US24178700P2000-10-202000-10-20
US24182600P2000-10-202000-10-20
US24178500P2000-10-202000-10-20
US24180800P2000-10-202000-10-20
US24096000P2000-10-202000-10-20
US24122100P2000-10-202000-10-20
US60/241,7862000-10-20
US60/241,7852000-10-20
US60/241,8082000-10-20
US60/241,8092000-10-20
US60/241,2212000-10-20
US60/241,7872000-10-20
US60/240,9602000-10-20
US60/241,8262000-10-20
US24461700P2000-11-012000-11-01
US60/244,6172000-11-01
US24660900P2000-11-082000-11-08
US24647400P2000-11-082000-11-08
US24661300P2000-11-082000-11-08
US24647700P2000-11-082000-11-08
US24652800P2000-11-082000-11-08
US24647600P2000-11-082000-11-08
US24661000P2000-11-082000-11-08
US24647500P2000-11-082000-11-08
US24661100P2000-11-082000-11-08
US24652600P2000-11-082000-11-08
US24652500P2000-11-082000-11-08
US24652700P2000-11-082000-11-08
US24653200P2000-11-082000-11-08
US60/246,4742000-11-08
US60/246,6092000-11-08
US60/246,4752000-11-08
US60/246,5282000-11-08
US60/246,5242000-11-08
US60/246,5232000-11-08
US60/246,6132000-11-08
US60/246,4772000-11-08
US60/246,4782000-11-08
US60/246,6102000-11-08
US60/246,5272000-11-08
US60/246,4762000-11-08
US60/246,5322000-11-08
US60/246,5262000-11-08
US60/246,5252000-11-08
US60/246,6112000-11-08
US60/249,2142000-11-17
US60/249,2972000-11-17
US60/249,2452000-11-17
US60/249,2112000-11-17
US60/249,2182000-11-17
US60/249,2642000-11-17
US60/249,2102000-11-17
US60/249,2072000-11-17
US60/249,2652000-11-17
US60/249,2132000-11-17
US60/249,2162000-11-17
US60/249,2992000-11-17
US60/249,3002000-11-17
US60/249,2122000-11-17
US60/249,2092000-11-17
US60/249,2442000-11-17
US60/249,2172000-11-17
US60/249,2082000-11-17
US60/249,2152000-11-17
US60/250,3912000-12-01
US60/250,1602000-12-01
US60/251,0302000-12-05
US60/256,7192000-12-05
US60/251,9882000-12-05
US60/251,4792000-12-06
US60/251,8562000-12-08
US60/251,9902000-12-08
US60/251,8682000-12-08
US60/251,9892000-12-08
US60/251,8692000-12-08
US60/254,0972000-12-11
US60/259,6782001-01-05

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US09/908,711Continuation-In-PartUS20020045230A1 (en)2000-08-142001-07-20Nucleic acids, proteins, and antibodies

Publications (3)

Publication NumberPublication Date
WO2001055326A2 WO2001055326A2 (en)2001-08-02
WO2001055326A3true WO2001055326A3 (en)2001-09-07
WO2001055326A8 WO2001055326A8 (en)2001-09-07

Family

ID=37897731

Family Applications (1)

Application NumberTitlePriority DateFiling Date
PCT/US2001/001347WO2001055326A2 (en)2000-01-312001-01-17Nucleic acids, proteins, and antibodies

Country Status (1)

CountryLink
WO (1)WO2001055326A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA2496312A1 (en)*1999-12-012001-06-07Kevin P. BakerColon tumour marker pro4799 polypeptides and nucleic acids encoding the same
WO2001096375A2 (en)*2000-06-162001-12-20Millennium Pharmaceuticals, Inc.33358, a novel human ankyrin family member and uses thereof
US6822082B2 (en)*2000-06-302004-11-23Zymogenetics, Inc.Polynucleotides for mammalian secreted protein, Z1055G2P
JP3749709B2 (en)*2001-01-092006-03-01株式会社Ｇｂｓ研究所 Human glioma antigen and preparation method thereof
DE10106835A1 (en)*2001-02-142002-09-05Basf Lynx Bioscience Ag Signal transduction proteins 15B3, 15B3-1 and 15B3-2 and underlying DNA sequences
AU2003243151A1 (en)2002-08-162004-03-03Agensys, Inc.Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
JPWO2004022753A1 (en)*2002-08-302005-12-22アンジェスＭｇ株式会社 Actin-related novel cytoskeletal protein LACS
DE10254601A1 (en)2002-11-222004-06-03Ganymed Pharmaceuticals Ag Gene products differentially expressed in tumors and their use
DE102004024617A1 (en)2004-05-182005-12-29Ganymed Pharmaceuticals Ag Differentially expressed in tumors gene products and their use
EP1790664A1 (en)2005-11-242007-05-30Ganymed Pharmaceuticals AGMonoclonal antibodies against claudin-18 for treatment of cancer
WO2013167153A1 (en)2012-05-092013-11-14Ganymed Pharmaceuticals AgAntibodies useful in cancer diagnosis
WO2013174404A1 (en)2012-05-232013-11-28Ganymed Pharmaceuticals AgCombination therapy involving antibodies against claudin 18.2 for treatment of cancer
SG11201503593UA (en)2012-11-132015-06-29Biontech AgAgents for treatment of claudin expressing cancer diseases
WO2014127785A1 (en)2013-02-202014-08-28Ganymed Pharmaceuticals AgCombination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014146672A1 (en)2013-03-182014-09-25Ganymed Pharmaceuticals AgTherapy involving antibodies against claudin 18.2 for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2001038332A1 (en)*1999-11-242001-05-31Merck & Co., Inc.Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2001038332A1 (en)*1999-11-242001-05-31Merck & Co., Inc.Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors

Also Published As

Publication numberPublication date
WO2001055326A2 (en)2001-08-02
WO2001055326A8 (en)2001-09-07

Similar Documents

PublicationPublication DateTitle
WO2001055311A8 (en)Nucleic acids, proteins, and antibodies
WO2001090304A3 (en)Nucleic acids, proteins, and antibodies
WO2001054472A8 (en)Nucleic acids, proteins, and antibodies
WO2001055306A8 (en)Nucleic acids, proteins, and antibodies
WO2001055326A8 (en)Nucleic acids, proteins, and antibodies
WO2002026930A3 (en)Nucleic acids, proteins, and antibodies
WO2001055168A8 (en)Nucleic acids, proteins and antibodies
WO2001055440A8 (en)Nucleic acids, proteins, and antibodies
WO2002072763A3 (en)Nucleic acids, proteins, and antibodies
WO2001055167A8 (en)Nucleic acids, proteins, and antibodies
WO2001055162A8 (en)Nucleic acids, proteins, and antibodies
WO2001055449A8 (en)Nucleic acids, proteins, and antibodies
WO2001055305A3 (en)Nucleic acids, proteins, and antibodies

Legal Events

DateCodeTitleDescription
AKDesignated states

Kind code of ref document:A2

Designated state(s):AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

ALDesignated countries for regional patents

Kind code of ref document:A2

Designated state(s):GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AKDesignated states

Kind code of ref document:C1

Designated state(s):AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

ALDesignated countries for regional patents

Kind code of ref document:C1

Designated state(s):GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFPCorrected version of a pamphlet front page
CR1Correction of entry in section i

Free format text:PAT. BUL. 31/2001 UNDER "PUBLISHED", ADD "WITH SEQUENCE LISTING PART OF DESCRIPTION PUBLISHED SEPARATELY IN ELECTRONIC FORM AND AVAILABLE UPON REQUEST FROM THE INTERNATIONAL BUREAU."

121Ep: the epo has been informed by wipo that ep was designated in this application
REGReference to national code

Ref country code:DE

Ref legal event code:8642

WWEWipo information: entry into national phase

Ref document number:2395734

Country of ref document:CA

WWEWipo information: entry into national phase

Ref document number:2001912659

Country of ref document:EP

WWWWipo information: withdrawn in national office

Ref document number:2001912659

Country of ref document:EP

NENPNon-entry into the national phase

Ref country code:JP

DFPERequest for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DPE2Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
[8]ページ先頭
©2009-2025 Movatter.jp